Toward a standardized validation framework in robotic surgery AI: proposal for an Surgical Validation Scoring (SURVAS) system

Abstract

To the Editor, The adoption of AI in robotic surgery has progressed more quickly than its validation. Models that appear impressive in controlled environments but frequently fall short in real-world translation are prevalent in the literature. In the absence of established standards, patient safety may be overshadowed by excitement. We contend that the only way to stop the early adoption of risky or non-generalizable systems is to use a systematic, surgery-specific validation rubric, like the Surgical Validation Scoring (SURVAS) system. Preoperative risk assessment was the most common application of models, and better decision making was the most often mentioned advantage[1]. However, the majority of research ends at surrogate endpoints. SURVAS requires the entire chain to be demonstrated: model → decision modification → quantifiable clinical effect. “Improved decision-making” is merely hyperbole without this. Standardized validation systems are lacking, and assessments of AI model implementations in surgery are scarce and inconsistent in the literature[1]. This recurring criticism draws attention to a structural flaw. With the use of external cohorts, pre-established measurements, and stress testing, SURVAS turns it into a prescriptive checklist with measurable thresholds. This substitutes auditable evidence for imprecise assurances. The lack of strong external validation has contributed to the limited clinical use of artificial intelligence models based on digital pathology for the diagnosis of lung cancer[2]. AI in robots runs the same risk. Before a model may progress past the pilot phase, SURVAS requires independent centers and separates out several forms of external validation (temporal, geographic, and vendor-diverse). The absence of consistent performance standards for artificial intelligence (AI)/machine learning-based medical devices poses a significant regulatory difficulty since it is hard to compare systems or evaluate generalizability[3]. In order to address this, SURVAS requires challenge sets that replicate the worst-case scenarios and carefully selected benchmark datasets. This innovation guarantees that models are evaluated under surgical stress in addition to steady-state conditions. In this study, we examine how AI models are currently used and validated in clinical surgical settings and suggest a brand-new classification scheme. The SURVAS is a validation categorization system[1]. In contrast to general AI checklists, SURVAS includes robotic-specific modules that represent the realities of human–machine interaction, such as controller failure simulation, kinematic consistency, and latency sensitivity. The accuracy and patient safety of these models must be guaranteed before AI is extensively used. Without adequate validation, there is a chance that AI models will be used in practice without enough proof of their accuracy and safety, which could result in less-than-ideal patient outcomes[1]. In order to prevent harmful models from being used in clinical trials, SURVAS offers subgroup fairness levels, explicit harm models, and a pre-regulatory filter function. To match incentives with safety, journals and IRBs can demand an SURVAS score before approving a proposal. Since AI models have just recently become popular, there are not many thorough evaluations of their current application and validation. In this study, we provide a comprehensive assessment of existing validation techniques and describe their applications and uses in surgery. SURVAS (Surgery Validation Score) is a new validation quality score that we suggest for AI models used in surgery. To assist physicians in understanding the level of validation of AI models for use in surgery, SURVAS was created as a categorization system[1]. SURVAS creates a transparency loop that is lacking in the existing research by proposing a public registry of scores, validation splits, and model metadata in order to reach beyond academics. A statistical analysis of the responses (N = 197) revealed that the mitochondrial dysfunction–related cute stress response utility and negative attitude towards robot subscales had the strongest relationships with the willingness to participate in robotic surgery and a favorable attitude towards surgical robots[4]. By making validation accessible through public ratings, plain-language summaries, and evidence-linked patient-facing badges, SURVAS enhances regulatory dossiers and patient trust. The use of artificial intelligence in autonomous robotic surgery and surgical decision making requires transparency and accountability[5]. This is operationalized by SURVAS through penalties for homogeneity, federated validation options, and dataset provenance requirements. Unregulated AI systems in use could seriously jeopardize patient safety if they are not properly monitored[6]. SURVAS incorporates post-market surveillance, including required re-scoring, adverse decision reporting, and drift detection, to lessen this. The safety loop that is missing from existing frameworks is closed when a model is reported or withdrawn for failing to maintain its score. To sum up, SURVAS is a practical, auditable, and robotic-specific validation solution; it is not cosmetic. It offers regulators, physicians, and patients a clear defense against the hasty deployment of AI by requiring external validation, adversarial stress tests, subgroup fairness, and post-market monitoring. The promise of AI in robotic surgery cannot be realized as a reliable clinical reality until such criteria are incorporated. This letter to the editor adheres to the Transparency in the Reporting of Artificial Intelligence in Research (TITAN) guideline[7].

Ähnliche Arbeiten